Why You Don't Need to Cycle CJC-1295 or Tesamorelin
Most people running CJC-1295 and Ipamorelin together treat the combination as a single thing, which means they cycle both of them together, and that makes sense if you assume both peptides work the same way. But they don't, and that assumption is what leads to unnecessary breaks from something that doesn't actually need a break.
To understand why, you need the full picture first.
Your pituitary gland releases growth hormone in pulses, and those pulses are controlled by two separate input systems. The first system runs through something called GHRH receptors, which stands for growth hormone releasing hormone receptors, and these are the receptors that respond to natural GHRH from your hypothalamus and to peptides like CJC-1295 and tesamorelin. The second system runs through something called ghrelin receptors, which are the receptors that respond to the hunger hormone ghrelin and to peptides like Ipamorelin and MK-677. Both systems tell the pituitary to release growth hormone, but they do it through completely separate molecular pathways, and they behave very differently when you stimulate them continuously.
That distinction is the whole point of this article.
When you stimulate a receptor system continuously, many receptor types will start pulling themselves off the cell surface as a protective response. The cell is essentially saying the signal is too loud and too constant, so it reduces the number of receivers it has available. This process runs through a protein called beta arrestin, which tags activated receptors and triggers their removal from the cell membrane and into the interior of the cell where they are temporarily unavailable. Fewer receptors on the surface means a weaker response to the same dose. That is receptor desensitization, and it is the reason cycling exists as a concept in the first place.
Ghrelin receptors go through this process.
A 16-week human trial tracked what happens to growth hormone response when you continuously stimulate ghrelin receptors with a compound called hexarelin, which works through the same receptor system as Ipamorelin. By week 16, the growth hormone response had declined roughly 45 percent from where it started. Not a small drift. Nearly half the response was gone. But when subjects stopped for four weeks, the response came fully back to baseline. The receptors weren't permanently damaged. They just needed time to recycle back to the surface, and four weeks was enough to accomplish that. That is exactly where the standard three months on, one month off framework comes from, and it is legitimate.
But GHRH receptors don't follow the same pattern.
The evidence here is direct and from long-term clinical data. Tesamorelin is a stabilized analog of natural GHRH, meaning it binds and activates the same GHRH receptors that CJC-1295 activates. In the Phase 3 trials that led to FDA approval, patients received daily tesamorelin injections for 52 consecutive weeks, and IGF-1 levels, which reflect sustained growth hormone output over time, stayed elevated the entire time with no measurable decline. If GHRH receptor desensitization were occurring at a clinically meaningful level, you would expect IGF-1 to drift downward somewhere in that 52-week window. It didn't.
The reason likely comes down to half-life and receptor recovery time.
Tesamorelin has a half-life of roughly 26 to 30 minutes. You inject it, it peaks, it stimulates the receptor, and then it clears the system within an hour or so. That means the GHRH receptor gets a brief discrete signal once a day and then has the remaining 23 or more hours to complete its normal recycling process before the next dose arrives. The receptor system never gets the kind of sustained, uninterrupted stimulation that forces internalization to accumulate faster than recovery can keep up.
Ipamorelin doesn't follow the same pattern in practice because ghrelin receptors appear to be more sensitive to the cumulative load of repeated stimulation, and the data on compounds like MK-677, a ghrelin receptor agonist taken orally once daily for two years continuously, actually showed maintained GH and IGF-1 elevation, which complicates the picture slightly. Some researchers think the severity of desensitization with ghrelin receptor agonists is dose and frequency dependent rather than simply a product of continuous use. But that data is in healthy older adults using a specific oral compound, so it may not map cleanly onto injectable Ipamorelin protocols. The 45 percent decline at 16 weeks with continuous hexarelin use is the most direct human data available for this receptor class, and it argues for respecting a cycling window.
The practical conclusion is clean. If you are running CJC-1295 and Ipamorelin together, the reason you cycle is the Ipamorelin, not the CJC. You could in theory keep the CJC running through your break from Ipamorelin and the GHRH receptor side of the equation would not suffer for it, though most people just take the break entirely for simplicity. If you are running tesamorelin by itself, there is no published human data suggesting you need to cycle it at all, and there is 52 weeks of continuous dosing data suggesting you don't.
The bigger point here is that receptor systems are not interchangeable just because two compounds accomplish the same downstream result.
CJC and Ipamorelin both raise growth hormone, and that shared outcome makes them feel like one thing. But the pathway they use to get there is independent at every step, which is something that has been directly confirmed in perifused rat pituitary cell research showing that saturating one receptor system has no effect on the responsiveness of the other. The outputs converge. The mechanisms don't.
Cycling advice that ignores this distinction isn't wrong exactly, it's just being applied to the wrong target. The cycle is protecting the ghrelin receptor. The GHRH receptor didn't need protecting to begin with.
References
- Rahim A, Shalet SM. Does desensitization to hexarelin occur? Growth Horm IGF Res. 1998;8 Suppl B:141-143 — 16-week human trial showing 45% GH response decline with continuous ghrelin receptor stimulation, full recovery after 4 weeks off. Source
- Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. NEJM. 2007 — Tesamorelin daily dosing for 26 weeks with sustained IGF-1 elevation. Source
- FDA Prescribing Information. EGRIFTA (tesamorelin). 2010/2025 — 52-week pooled Phase 3 data showing sustained IGF-1 and VAT reduction through week 52
- Blake AD, Smith RG. Desensitization studies using perifused rat pituitary cells. J Endocrinol. 1991;1291:11-19 — Proved GHRH and ghrelin receptor systems are independent with no cross-desensitization. Source
- Nass R et al. Effects of an oral ghrelin mimetic on body composition in healthy older adults. Ann Intern Med. 2008;1499:601-611 — MK-677 ghrelin mimetic maintained GH/IGF-1 elevation for 2 years of continuous use. Source
Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness
If this is the kind of information you want access to on a daily basis, the community is free and there are full courses on training, nutrition, hormones, and supplementation inside. You can ask questions and post your own labs and get feedback from me and from the community.